Storm chaser shares memories of 2019 Linwood tornado
Communities had to rebuild, but luckily no lives were lost. The storm turned out to be one of the most significant in history for the scientific community.
FOX4 Newsletters: Sign up for daily forecasts and Joe's Weather Blog in your inbox
In the six years since the devastating Linwood tornado we've heard from the survivors, who rode out the EF-4 in their homes.
'Had Jesus on my side, I lived through it,' Linwood resident Dennie Roberts, whose wife was killed in Kansas City's 2003 tornado, said.
FOX4 also spoke with thrill seekers who were sent flying in storm chasing tour vans.
'Immediately it just flipped us and we just bounced and rolled and banged like metal for what seemed like forever,' Jeff Lieberman said on the tornado's first anniversary.
That day as FOX4 meteorologists were watching the radar and FOX4 crews were first on the scene to the damage alerting first responders to the immediate need extreme meteorologist and storm chaser Reed Timmer and his team were also watching the super cell as it formed south of Lawrence, Kansas.
Timmer shared memories this week on .'
Joe's Blog: So, why has it been so gray lately (WED-5/28)
'It was wrapped in rain and we chased the storm for a little while it produced a brief tornado in the rain and we knew it was gearing up to produce a large one,' Timmer recalled. As the tornado formed Timmer was trying to pull off something he hadn't been able to do before on a storm of its magnitude. The problem was the tornado was rain wrapped.
'You almost have to get into the path of the tornado to be able to see it back in the inflow notch and that's a very dangerous place to be,' Timmer explained.Still they were able to launch a sensor called 'Dorothy' into the mile-wide twister recording wind speeds of 190 miles per hour, and thermodynamics like pressure fall, temperature and relative humidity.
But as the sensor and parachute climbed in the mesocyclone to heights of more than 27,000 feet there was just one problem after the tornado passed and clean up began, finding it. Thankfully, 'Dorothy' was located 30 miles away in Leavenworth, Kansas while pots from Free State growers were found 50 miles away in Smithville, Missouri.
Download the FOX4 News app on iPhone and Android
With that single sensor recovered its the first time they were ever able to get data recovered at 10 times per second. Timmer says hopefully data collected will help go along way in better understanding tornadoes and maybe one day even preventing them.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Model Responds To Fake Astronomer CEO Daughter Video
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Julie Tuzet, a French model and songwriter, has responded after a viral TikTok video appeared to claim that she was the daughter of Astronomer CEO Andy Byron. "I am not the CEO's daughter," she said in a video. Why It Matters Byron and Kristin Cabot, Astronomer's head of human resources, were seen on a jumbotron embracing at a Coldplay concert in Foxborough, Massachusetts, last week. Footage of the incident, which showed the couple breaking apart in a panic, was later uploaded to TikTok, where it became a viral sensation. Byron, who is married to Megan Kerrigan Byron, has resigned from his CEO position amid the fallout. His embrace of Cabot has been widely parodied on- and offline. The moment has also renewed a national discussion about privacy in the digital age. A composite image showing a screenshot of Astronomer CEO Andy Byron and Chief People Officer Kristin Cabot at a Coldplay concert and a stock photo of the TikTok app on an iPhone screen. A composite image showing a screenshot of Astronomer CEO Andy Byron and Chief People Officer Kristin Cabot at a Coldplay concert and a stock photo of the TikTok app on an iPhone screen. TikTok/Screenshot/5./15 West What To Know A video that has circulated widely across social media shows a young woman standing by a firepit, with a text overlay saying, "Reconnecting with life after your dads affair makes national news." While the video does not explicitly name Byron, given the intense virality of the jumbotron footage and subsequent fallout, he appears to be the "dad" referenced in the video. Though the video features Tuzet, she has no connection to Byron. In a video posted on TikTok, the model said: "You probably have seen this video of me at a fireplace 'reconnecting' with nature. It's just someone who stole my videos and my content from TikTok to create this fake news. And it's going viral." Speaking with Newsweek by email, Tuzet said, "This is unfortunately not the first time my content is being stolen, and I'd truly appreciate this to be the last time." "I woke up the other day with 100 messages of my friends and family sending me this viral video of myself taken originally in Guatape, Colombia, three months ago," she said. "It is me in the video, but the text is not mine, and the account is not mine neither," the songwriter continued. Her TikTok video calling out the stolen content has been viewed more than 197,000 times as of reporting. It's not the only video she has posted about the situation. In another post, she shared a clip of herself in front of the firepit with a text overlay that said, "Reconnecting with nature after getting impersonated on TikTok by some troll using my videos for clout once again." That video has been viewed more than 162,000 times. Following the viral jumbotron moment, "Andy Byron" quickly jumped to the top of Google's trending searches. Social media users have closely followed the incident, which has all the ingredients to make a modern scandal. What People Are Saying Julie Tuzet told Newsweek by email: "My face has been all over the news in the past days as 'The CEO's daughter' … I am a French model and singer-songwriter from Paris that just had her identity stolen." What Happens Next Online misinformation has long been a concern, but in the age of AI, fake news is rapidly increasing.
Hamilton Spectator
4 hours ago
- Hamilton Spectator
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation. The key primary outcomes from the SRP indicate that: 'The successful execution of the PoNS SRP and the positive results of the clinical trials mark an important milestone in advancing the standard of care for stroke and offer individuals suffering from gait/balance disability a meaningful therapeutic option to rehabilitate and regain their functionality,' stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. 'We look forward to releasing the SRP's study results this quarter and to continuing working closely with FDA under the upcoming application for authorization of the Agency's breakthrough designated PoNS device.' Helius started the SRP in March 2024 after a positive interaction with the FDA on the data development program, study design, and endpoints. The SRP includes two pivotal Sponsor-initiated clinical studies: a double-blind, randomized controlled trial and a single-arm trial, which began in April 2024. The SRP is also supported by a pilot investigator-initiated, double-blind randomized controlled trial by Dr. Steve Kautz and Dr. Mark Bowden of MUSC (SC) and Brook Rehabilitation (FL) respectively, which began late in the fall of 2023. All three clinical trials enrolled patients from the same patient population and shared the same study structure/endpoints aimed at establishing the efficacy and safety of PoNS in people with gait deficit due to chronic stroke. A total of 159 patients were enrolled across the three studies, with 130 patients completing both the 12-week study treatment phase and the 12-week post treatment follow-up period, at 10 clinical sites including centers of excellence for stroke rehabilitation across the US and Canada. Study participants received the (active or sham) study treatment in combination with physical therapy according to the current guidelines for functional rehabilitation of people with chronic stroke. The primary endpoints for all three studies included improvement of gait and/or balance deficit after 12 weeks of study treatment with two key multiplicity-controlled secondary endpoints assessing risk of falling and 12-week durability of effect. The double-blind randomized clinical trial met the primary endpoint of demonstrating statistically significant greater improvements in gait and/or balance deficit due to stroke with active PoNS Therapy with and without including additional data from an open label study using statistical methods to balance baseline characteristics. The studies also demonstrated minimal incidence of adverse events and confirmed good treatment tolerability. 'More than 7 million patients suffer from the symptoms of stroke and about 80% of them have balance and gait deficit, resulting in a large addressable market with a high risk of falling,' said Dane Andreeff, Helius' CEO. 'We look forward to a positive outcome of the submission to the FDA and to bringing this impactful treatment to everyone living with the consequences of a stroke.' The PoNS has not yet been approved in the United States for use in stroke rehabilitation and remains investigational for this use. Helius is planning to file a submission to the FDA for an indication in stroke during the third quarter of 2025 under its current FDA breakthrough designation for stroke. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit . About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit . Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the PoNSTEP study results, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or . The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip Taylor Gilmartin Group investorrelations@
Yahoo
10 hours ago
- Yahoo
Northwest DC flooding traps drivers, several rescued
WASHINGTON (DC News Now) — Several people were rescued in Northwest D.C. after multiple drivers were trapped in floodwater Saturday, according to the DC Fire and EMS Department. MCFRS: Multiple people rescued after being trapped in floodwaters Around 5:40 p.m., three people were rescued unharmed from a car trapped in high water near 3rd Street and Underwood Street NW. Crews also reported multiple disabled vehicles in the 7100 block of Piney Branch Rd NW, where several people were safely removed from a car that was submerged in the water. No injuries have been reported so far in the flooding. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
